Relief Therapeutics Holding AG (RLFTF)

[Inelgr]

Yup. The 28 day marker isn't the key. The 60 day marker is. At least, in terms of mortality rates.

That of course, doesn't address the very significantly positive length of hospital/ICU stay data.

They have never reported, so far as I know, significant mortality improvement at 28 days.

In fact, their current 28 day data is THE SAME as it was before. Months ago.

So nothing has changed in that regard. In other words, no negative news.

Zyesami remains the front runner as far as therapeutics go.